Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2A | O00443 | 1/20 | 0.85 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.85 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946732 | 0.92 | PIK3C2A (0.82) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL947933 | 0.92 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1950746 | 0.92 | PIK3C2A (0.82) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL944686 | 0.92 | PIK3C2A (0.81) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL14813306 | 0.89 | PIK3C2A (0.76) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL945539 | 0.89 | PIK3C2A (0.77) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL944623 | 0.88 | PIK3C2A (0.84) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL944443 | 0.88 | PIK3C2A (0.75) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL945952 | 0.88 | PIK3C2A (0.83) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB | |
| SCHEMBL14912770 | 0.87 | PIK3C2A (0.66) | PIK3C2APIK3C2BPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | claimed |
| US-8710054-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-04-29 | — | — | US | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-28 | — | — | US | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | PIK3C2A 87/4885PIK3C2B 78/4885PIK3CD 42/4885 |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | PIK3C2A 87/4885PIK3C2B 78/4885PIK3CD 42/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PIK3C2A 65/4885PIK3C2B 62/4885PIK3CD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.